Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Prostate Cancer Therapeutics Market Size Forecast: How Large Could The Market Become By 2030?
The prostate cancer therapeutics market has experienced robust expansion in recent years, with projections indicating an increase from $12.88 billion in 2025 to $13.96 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.4%. This historical growth has been driven by factors such as a higher prevalence of prostate cancer, an aging male demographic, progress in oncology drug development, the provision of cancer care within hospital settings, and a greater emphasis on cancer screening initiatives.
The size of the prostate cancer therapeutics market is anticipated to experience robust expansion over the coming years. By 2030, it is projected to reach $19.25 billion, reflecting a compound annual growth rate (CAGR) of 8.4%. Several factors are driving this forecasted growth, including the adoption of precision oncology, the rise of biomarker-driven therapies, an increase in oral oncology drugs, an expanding immunotherapy pipeline, and higher healthcare spending. Key trends shaping this period encompass a growing preference for targeted therapies, increased utilization of PARP inhibitors, the broader application of immunotherapy in oncology, a transition toward oral cancer medications, and treatment selections guided by precision medicine.
Download A Free Sample Report For Comprehensive Market Insights:
Prostate Cancer Therapeutics Market Growth Momentum: Which Factors Are Influencing Demand?
The rising prevalence of prostate cancer is anticipated to drive expansion in the prostate cancer therapeutics market moving forward. This disease involves the formation of malignant cells within the prostate gland tissues, predominantly affecting older men. Its growing incidence is linked to an aging population, as the likelihood of developing the condition significantly increases with age, and extended life expectancy allows more men to reach ages where it commonly occurs. Prostate cancer therapeutics are designed to manage the illness by focusing on cancerous cells, decelerating disease progression, and enhancing quality of life through interventions like surgery, radiation, hormone therapy, and emerging options such as immunotherapy. As an example, in January 2025, data from Prostate Cancer UK, a nonprofit cancer research and advocacy organization based in the UK, revealed that diagnosed prostate cancer cases rose from 50,751 in 2022 to 55,033 in 2023. Consequently, the escalating incidence of prostate cancer is fueling growth in the prostate cancer therapeutics market.
Prostate Cancer Therapeutics Market Segment Analysis: What Are The Major Market Categories?
The prostate cancer therapeutics market covered in this report is segmented –
1) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other Therapies
2) By Drug Class: Androgen Receptor Inhibitors, GnRH Receptor Antagonists, PARP Inhibitors, Immune Checkpoint Inhibitors, Other Drug Classes
3) By Route Of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies
5) By End User: Clinics, Hospitals, Other End Users
Subsegments:
1) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors
2) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens
3) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines
4) By Targeted Therapy: PARP Inhibitors, Radioligand Therapy
5) By Other Therapies: Radiotherapy, Bone-Targeted Therapies, Cryotherapy, High-Intensity Focused Ultrasound
Prostate Cancer Therapeutics Market Trends Reshaping Industry Growth
Key players in the prostate cancer therapeutics sector are intensifying efforts to develop innovative treatments like a once-daily oral pill designed for advanced stages of the disease, aiming to boost patient adherence and enhance therapeutic results. This type of medication is taken each day to address metastatic castration-resistant prostate cancer by blocking the effects of testosterone on malignant cells. A notable example occurred in January 2024, when Zydus Lifesciences, a pharmaceutical firm based in India, introduced Rexigo, the country’s first daily oral tablet containing relugolix for those with advanced prostate cancer. This option serves as an accessible and cost-effective substitute for injectable hormone therapies, rapidly reducing testosterone levels to curb tumor progression, while also providing a more favorable cardiovascular risk profile. Since it is taken orally, patients no longer need to visit healthcare professionals for injections, significantly improving convenience. The introduction of this treatment marks a major step forward in managing prostate cancer within India, equipping both patients and physicians with a novel, practical, safer, and economical solution.
Prostate Cancer Therapeutics Market Leading Companies Driving Competitive Growth
Major companies operating in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Ferring B.V.
Access The Complete Prostate Cancer Therapeutics Market Report:
Prostate Cancer Therapeutics Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the prostate cancer therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model